RecruitingPhase 2NCT06246110

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Sponsor

Eikon Therapeutics

Enrollment

70 participants

Start Date

Feb 6, 2024

Study Type

INTERVENTIONAL

Conditions

NSCLC

Summary

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Phase 2 study is testing a new drug called EIK1001 in combination with pembrolizumab (an immunotherapy) and standard chemotherapy as a first-line treatment for people with stage 4 non-small cell lung cancer (NSCLC) — the most common type of lung cancer, at its most advanced stage. **You may be eligible if...** - You are 18 or older - You have been diagnosed with stage 4 NSCLC (squamous or non-squamous type) - Your cancer does not have specific gene mutations (like EGFR, ALK, ROS1) for which targeted drugs are already approved as first-line treatment - You have not yet received systemic treatment for your advanced lung cancer - You have at least one measurable tumor on scans - Your general health is good (ECOG performance status 0 or 1) **You may NOT be eligible if...** - Your lung cancer has an activating mutation for which a specific targeted therapy is approved - You have had prior systemic treatment for metastatic or advanced NSCLC - You have active or untreated brain metastases - You have autoimmune diseases that needed systemic treatment in the past 2 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEIK1001

EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist

DRUGPembrolizumab

PD-1 inhibitor

DRUGPaclitaxel

Chemotherapy

DRUGPemetrexed

Chemotherapy

DRUGCarboplatin

Chemotherapy

Locations(39)

Southern Cancer Care

Daphne, Alabama, United States

Ironwood Cancer and Research Center

Chandler, Arizona, United States

California Cancer Care Associates for Research & Excellence

Fresno, California, United States

California Research Institute

Los Angeles, California, United States

University of Southern California, Norris Comprehensive Cancer Center

Los Angeles, California, United States

Providence St Joseph Hospital, Center for Cancer Prevention and Treatment

Orange, California, United States

Sutter Health Institute for Medical Research

Sacramento, California, United States

Rocky Mountain Cancer

Lone Tree, Colorado, United States

Bioresearch Partner

Hialeah, Florida, United States

Memorial Cancer Institute

Hollywood, Florida, United States

Mid-Florida Hematology and Oncology Center

Orange, Florida, United States

Orlando Health Cancer Institute

Orlando, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Atlanta Piedmont Hospital

Atlanta, Georgia, United States

Kaiser Permanente Hawaii

Honolulu, Hawaii, United States

Illinois Cancer Specialists

Niles, Illinois, United States

Accelacare of Duly

Tinley Park, Illinois, United States

Indiana University Cancer Center

Indianapolis, Indiana, United States

Health Midwest Oncology Associates of Kansas

Overland Park, Kansas, United States

Cancer Center of Kansas

Wichita, Kansas, United States

Medstar Franklin Square Cancer Center at Loch Raven Campus

Baltimore, Maryland, United States

Maryland Oncology

Columbia, Maryland, United States

Jersey Shore University Medical Center/Meridian Hematology & Oncology

Neptune City, New Jersey, United States

New York Cancer and Blood Specialists

Babylon, New York, United States

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, United States

Weil Cornell Medical Center

New York, New York, United States

Albert Einstein College of Medicine, Jacobi Medical Center

The Bronx, New York, United States

Cancer and Blood Specialists of New York, White Plains Hospital

White Plains, New York, United States

Messino Cancer Centers

Asheville, North Carolina, United States

Gabrail Cancer Center

Canton, Ohio, United States

Willamette Valley

Eugene, Oregon, United States

Tennessee Cancer Specialists

Knoxville, Tennessee, United States

Baptist Cancer Center

Memphis, Tennessee, United States

Texas Oncology, Austin

Austin, Texas, United States

Texas Oncology, Bedford

Bedford, Texas, United States

The Center for Cancer and Blood Disorders

Fort Worth, Texas, United States

Blue Ridge Cancer Care Oncology Associates SW VA

Blacksburg, Virginia, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Shenandoah Oncology

Winchester, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06246110

Related Trials

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

NCT0662083527 locations

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143207 locations

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NCT075591231 location

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT041141361 location